Basis for lack of drug susceptibility of atypical mycobacteria.
about
Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complexAction of 1-isonicotinyl-2-palmitoyl hydrazine against the Mycobacterium avium complex and enhancement of its activity by m-fluorophenylalanineLiposome-encapsulated-gentamicin therapy of Mycobacterium avium complex infection in beige miceBroth microdilution testing of susceptibilities to 30 antimicrobial agents of Mycobacterium avium strains from patients with acquired immune deficiency syndromeActivity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamideA bone marrow-derived murine macrophage model for evaluating efficacy of antimycobacterial drugs under relevant physiological conditionsIn vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and M. tuberculosisActivities of fluoroquinolone, macrolide, and aminoglycoside drugs combined with inhibitors of glycosylation and fatty acid and peptide biosynthesis against Mycobacterium aviumPotential drug targets for Mycobacterium avium defined by radiometric drug-inhibitor combination techniques.Current trends in nontuberculous mycobacteria infections in Canadian children: A pediatric investigators collaborative network on infections in Canada (PICNIC) studyRole of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide.French multicenter study involving eight test sites for radiometric determination of activities of 10 antimicrobial agents against Mycobacterium avium complexReevaluation of envelope profiles and cytoplasmic ultrastructure of mycobacteria processed by conventional embedding and freeze-substitution protocolsMonoclonal infection involving Mycobacterium avium presenting with three distinct colony morphotypes.The Mycobacterium avium complexCharacterization of inhibition of Mycobacterium avium replication in macrophages by normal human serum.Evaluation of growth promotion and inhibition from mycobactins and nonmycobacterial siderophores (Desferrioxamine and FR160) in Mycobacterium aurum.Enhancement of drug susceptibility of Mycobacterium avium by inhibitors of cell envelope synthesis.Specific surface antigens of SmT variants of Mycobacterium avium.
P2860
Q28326449-F3C989A6-DEF5-46F1-A28C-B63A47D4FDAEQ28328609-D68988CE-2A01-480C-B968-86188E019FDAQ28335928-D8552955-C09E-44C4-969D-79B963E2CA9EQ28361676-9C236B94-5F76-4D11-97A9-782337A35594Q28367751-CA414B54-5328-4FC0-BDFB-11313B662026Q28368663-2D2ECBAE-F9C3-41BD-889E-C94C1C0F6081Q28369524-D3596C60-B1E8-482C-B061-C811AD0099ADQ28378705-2E52CC01-ECDF-402D-85D5-1548AAEA3803Q33760607-88F8AB5D-DBD8-445F-90A8-D1F17D2B6A10Q33885874-24E08DCD-C4DC-4705-97AE-87446BAA3EA5Q33991596-2E6711A4-32CD-44B9-BA56-81850AA5108EQ35112232-9C32ED33-06A2-4E6E-BDE1-88F07A8840B7Q36139238-C4CB9318-475B-43E4-8B79-44F63C22B57DQ36539933-92B861F8-1BDF-47E8-9C61-7D6BCBCE1F41Q36640345-2F8DEC9B-0073-4D1C-BFA5-9FE88D3E32A7Q36957273-15AA4766-9DB8-4808-8A51-12F7F50F2425Q39784808-39C25F1D-2847-4AF1-8480-B0F6A90689F9Q39815856-2EA116F5-18CF-4D55-857B-D146C18A56DFQ40177725-6EFC7795-5C59-42A5-BB1B-89BFFB003E7E
P2860
Basis for lack of drug susceptibility of atypical mycobacteria.
description
1981 nî lūn-bûn
@nan
1981年の論文
@ja
1981年論文
@yue
1981年論文
@zh-hant
1981年論文
@zh-hk
1981年論文
@zh-mo
1981年論文
@zh-tw
1981年论文
@wuu
1981年论文
@zh
1981年论文
@zh-cn
name
Basis for lack of drug susceptibility of atypical mycobacteria.
@en
type
label
Basis for lack of drug susceptibility of atypical mycobacteria.
@en
prefLabel
Basis for lack of drug susceptibility of atypical mycobacteria.
@en
P356
P1476
Basis for lack of drug susceptibility of atypical mycobacteria
@en
P2093
P304
P356
10.1093/CLINIDS/3.5.878
P577
1981-09-01T00:00:00Z